Equity Details
Price & Market Data
Price: $29.64
Daily Change: +$2.00 / 6.73%
Daily Range: $26.95 - $29.83
Market Cap: $1,835,263,872
Daily Volume: 4,094,486
Performance Metrics
1 Week: 37.52%
1 Month: 62.39%
3 Months: 17.77%
6 Months: 4.71%
1 Year: 121.3%
YTD: 21.60%
About uniQure N.V. (QURE)
Financial summary for uniQure N.V. (QURE). Price: 29.64, daily change: +$2.00 / 6.73%. Market cap: 1,835,263,872. Performance for all periods at a glance.
Company Details
Employees: 221
Sector: Health technology
Industry: Biotechnology
Country: Netherlands
Details
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.